Password reminder
No account yet? Register Free
About Us Advertising Info Contact Us Client Login
biotechdaily.com
Drug Discovery
Features Subscription Partner Sites Journal Info
SANYO EUROPE LTDROCHE APPLIED SCIENCEHTL Lab Solutions

Malaria Parasites Are Killed by a Novel Transition State Analog Drug in a Monkey Model

By BiotechDaily International staff writers
Posted on 19 Dec 2011


A novel transition state analog drug cleared the malaria parasite Plasmodium falciparum from the blood of infected monkeys by preventing the parasites from using the purine precursors they need to synthesize DNA.

Transition state analogs are chemical compounds with a chemical structure that resembles the transition state of a substrate molecule in an enzyme-catalyzed chemical reaction. Transition state analogs usually do not undergo a chemical reaction and can act as enzyme inhibitors by blocking their active site.

Investigators at the Albert Einstein College of Medicine (New York, NY, USA) worked with a small group of Aotus monkeys, which normally die as the result of P. falciparum infection. In the current study, after infection with the malaria parasite the monkeys were treated with the experimental drug BCX4945 (DADMe-Immucillin-G). This drug – a member of the transition analog class of reagents – acts by blocking the activity of the enzyme purine nucleoside phosphorylase (PNP). PNP is used by P. falciparum to manufacture the purine precursor hypoxanthine, which the parasites use to make DNA.

Results published in the November 11, 2011, online edition of the journal PLoS ONE revealed that oral administration of BCX4945 for seven days resulted in parasite clearance in otherwise lethal infections of P. falciparum in Aotus monkeys. Withholding the drug caused the parasites to reappear. BCX4945 caused depletion of hypoxanthine from the monkeys’ blood, demonstrating inhibition of both human and malarial PNP in vivo. The molecular action of BCX4945 was demonstrated in crystal structures of human and P. falciparum PNPs.

The efficacy, oral availability, chemical stability, unique mechanism of action, and low toxicity of BCX4945 demonstrate the potential for use of this drug in combination therapies with other antimalarial agents.

“Inhibiting PNP differs from all other current approaches for treating malaria,” said senior author Dr. Vern Schramm, professor of biochemistry at the Albert Einstein College of Medicine. “For that reason, BCX4945 fits well with the current World Health Organization protocols for malaria treatment, which call for using combination-therapy approaches against the disease.”

Related Links:

Albert Einstein College of Medicine






Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to BiotechDaily.com and get complete access to news and events that shape the world of biotechnology.
Free digital version edition of Bio Research International sent by email on regular basis
Free print version of Bio Research International magazine
(available only outside USA and Canada).
Free and unlimited access to back issues of Bio Research International in digital format
Free Bio Research International Newsletter sent every 2 weeks containing the latest news
Free breaking news sent via email
Free access to Events Calendar
Free access to LinkXpress new product services
REGISTRATION IS FREE AND EASY!


Click here to Register

Sign in: Registered website members
Username: Password:
Forgot username/password? Click here!
Sign in: Registered magazine subscribers
Subcode: Last Name:
What is SUBCODE?

ADVERTISEMENT
GLOBETECH PUBLISHING



LC/GC System
LC/GC System
Sample Preparation System
Sample Preparation System
High-Throughput Solution
High-Throughput Solution

More Products

Latest Drug Discovery News

LinkXpress
Click for LinkXpress
Reader Inquiry Service
Enter code to receive information:
Where I can find code?
Featured Video
BioTek:
The Race

View Video
Featured Whitepaper
ELGA LABWATER:
Why pure water is important in modern chromatography

Download Whitepaper
Events
ELA 2012 - European Lab Automation.
30 May 2012 - 31 May 2012


Bio International 2012.
18 Jun 2012 - 21 Jun 2012


ACHEMA 2012.
18 Jun 2012 - 22 Jun 2012


More events
Latest Issue

View Digital Edition
Subscribe / Renew
HTL Lab Solutions
WEALTEC BIOSCIENCE CO. LTD
VISION-SCIENCES, INC.
BRAND GMBH + CO
  biotechdaily.com Copyright © 2000-2012 Globetech Media. All rights reserved.
Privacy Policy